|John C. Martin, PhD|
Chairman and Chief Executive Officer
|Dr. Martin joined Gilead Sciences in 1990 and currently serves as Chairman of the Board of Directors and Chief Executive Officer. He served as President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation.|
Dr. Martin serves on the University of Southern California Board of Trustees.
Dr. Martin previously served as President of the International Society for Antiviral Research, Chairman of the Board of Directors of BayBio and Chairman of the Board of Directors of the California Healthcare Institute (CHI). He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Directors of the Biotechnology Industry Organization, the Board of Directors for CHI, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administration's Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS.
Dr. Martin holds a PhD in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.
|John F. Milligan, PhD|
President and Chief Operating Officer
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. Dr. Milligan is a member of the boards of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization, and Pacific Biosciences of California, Inc. He is also a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
|Norbert W. Bischofberger, PhD|
Executive Vice President, Research and Development and Chief Scientific Officer
|Dr. Bischofberger joined Gilead Sciences in 1990 and has served Executive Vice President for Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech’s DNA Synthesis Group from 1986 until 1990.
Dr. Bischofberger received a PhD in organic chemistry from Zurich’s Eidgenossische Technische Hochshule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts.
|Robin L. Washington|
Executive Vice President and Chief Financial Officer
Ms. Washington joined Gilead in 2008 and is currently Executive Vice President and Chief Financial Officer overseeing the company’s finance, information technology and investor relations organizations. Prior to joining Gilead, Ms. Washington was Chief Financial Officer of Hyperion Solutions, which was acquired by Oracle Corporation in March 2007. She previously served in a number of executive positions with PeopleSoft, most recently in the role of Senior Vice President and Corporate Controller.
Ms. Washington is a member of the Board of Directors of Honeywell International, the Board of Directors of Salesforce.com and the Board of Visitors, Graziadio School of Business and Management, Pepperdine University. She is a certified public accountant and holds a bachelor's degree in business administration from the University of Michigan and an MBA from Pepperdine University.
|Gregg H. Alton|
Executive Vice President, Corporate and Medical Affairs
Gregg Alton joined Gilead Sciences in 1999. From 2000 to 2009 he served as General Counsel. In his current role, Mr. Alton is responsible for legal affairs, government affairs, medical affairs, public affairs and emerging market activities. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies.
Mr. Alton is a member of the boards of the AIDS Institute, BayBio (a San Francisco Bay Area life sciences industry organization), the Boys and Girls Clubs of Oakland and Celladon Corporation. He is also a member of the U.S. Government's Industry Trade Advisory Committee on Intellectual Property Rights, the advisory boards of UCSF Global Health Group, USC Schaeffer Center for Health Policy and Economics, Pharmozyme, Inc. and the Dean’s Advisory Council at Stanford Law School. In addition, he serves on Partners In Health’s Board of Trustees. Mr. Alton received a bachelor's degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University.
|Paul R. Carter|
Executive Vice President, Commercial Operations
Mr. Carter joined Gilead Sciences in April 2006. He most recently served as Senior Vice President of Gilead’s European commercial organization and during that time, he managed the company’s expansion across Europe and into Asia. In his current role, Mr. Carter is responsible for worldwide commercial operations. Prior to joining Gilead, Mr. Carter spent 15 years in the pharmaceutical industry with GlaxoSmithKline (GSK) and its legacy companies. During his time with GSK, Mr. Carter gained increasing levels of senior experience as General Manager in Europe and later as a Regional Head of the International business in Asia.
Mr. Carter holds a degree in Business Studies from the Ealing School of Business and Management (now merged into University of West London) and is a Fellow of the United Kingdom’s Chartered Institute of Management Accountants.
|John McHutchison, MD|
Executive Vice President, Clinical Research
|Dr. McHutchison joined Gilead in 2010. From 2010 to 2013, he served as Senior Vice President, Liver Disease Therapeutics. In his current role, he is responsible for Gilead’s development programs in liver diseases, oncology, respiratory diseases and inflammation. Prior to joining Gilead, Dr. McHutchison worked at Duke University Medical Center, where he served as Associate Director of the Duke Clinical Research Institute. He also held the positions of Professor of Medicine in the Division of Gastroenterology at Duke University Medical Center, Associate Director at Duke Clinical Research Institute and Co-Director of the Duke Clinical and Translational Science Award. Prior to his positions at Duke, Dr. McHutchison spent nearly 10 years at Scripps Clinic, most recently as Medical Director, Liver Transplantation. He also previously held an Assistant Professorship in Medicine at the University of Southern California. |
Dr. McHutchison received bachelor of medicine and bachelor of surgery degrees from the University of Melbourne, Australia, and completed his residency in internal medicine and a fellowship in gastroenterology at the Royal Melbourne Hospital. He is also a member of the Royal Australasian College of Physicians.
|Katie L. Watson|
Senior Vice President, Human Resources
Ms. Watson joined Gilead in February 2003 to manage compensation and HR information systems. In 2006 she was promoted to Senior Director of Total Rewards, and was appointed to Vice President of Employee Development and Rewards in 2012.Ms. Watson currently serves as Senior Vice President Human Resources. Before joining Gilead she was Manager of Compensation for Applied Biosystems (formerly Applera Corporation), led the HR consulting practice for TriNet and worked as an HR Business Partner for DE Shaw & Co.
Ms. Watson holds a degree in Psychology from the University of California at San Diego and a master's in Organizational Psychology from Columbia University.